COM_RESEARCHSTUDIES_DETAIL_AVAL_STATUS_4

Ph3 Randomized, Double-blinded, Placebo with Atezolizumab and Bevacizumab

This study is assessing the effectiveness and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when given with atezolizumab and bevacizumab as a first-line treatment for unresectable, locally advanced or metastatic patients with hepatocellular carcinoma (HCC). TIGIT is thought to play an important role in HCC's response to immunotherapy treatments such as atezolizumab. This study will assess whether the addition of tiragolumab to atezolizumab and bevacizumab will improve response and clinical outcomes.

Age & Gender

  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive

Contact the Team

Location

COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4

United States (Nationwide)

Additional Study Information

Principal Investigator

Jingquan Jia
Medicine- Oncology

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Kidney)

IRB Number

23-1402

ClinicalTrials.gov

NCT05904886

Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • research_for_me@unc.edu
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research